Avalo Therapeutics, Inc.
AVTX
$9.88
$0.515.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -66.37% | 5.51% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -66.37% | 5.51% | -100.00% |
| Cost of Revenue | 273.12% | 1,427.65% | 1,206.13% | 2,606.67% | -33.57% |
| Gross Profit | -273.12% | -1,427.65% | -3,736.73% | -156,075.00% | 21.90% |
| SG&A Expenses | 15.77% | 73.69% | 95.55% | 72.13% | 86.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 103.93% | 180.59% | 212.42% | 228.90% | 21.54% |
| Operating Income | -103.93% | -180.59% | -254.87% | -242.96% | -32.48% |
| Income Before Tax | -121.07% | 89.17% | -330.78% | 541.05% | 1,302.91% |
| Income Tax Expenses | 128.57% | 14.29% | 1,366.67% | -275.00% | 0.00% |
| Earnings from Continuing Operations | -121.09% | 89.16% | -332.65% | 540.65% | 1,301.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -121.09% | 89.16% | -332.65% | 540.65% | 1,301.79% |
| EBIT | -103.93% | -180.59% | -254.87% | -242.96% | -32.48% |
| EBITDA | -103.22% | -179.82% | -257.15% | -245.83% | -32.78% |
| EPS Basic | -145.54% | 96.05% | 66.03% | 103.67% | 102.99% |
| Normalized Basic EPS | -102.01% | 98.85% | 34.90% | 115.49% | 167.79% |
| EPS Diluted | 86.36% | 96.05% | 83.01% | 89.44% | 90.00% |
| Normalized Diluted EPS | -114.88% | 98.85% | 34.90% | 107.97% | 109.16% |
| Average Basic Shares Outstanding | 947.27% | 1,123.52% | 1,167.19% | 2,745.72% | 1,676.80% |
| Average Diluted Shares Outstanding | 41.50% | 1,123.52% | 1,167.19% | 5,433.09% | 13,050.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |